Pancreatic Cancer Research Expanded
Excerpts from a presentation by Hugh D. Riordan, M.D.
The receipt of a $52,000 grant from the New York based Wallace Genetic Foundation will help us continue our research into the treatment of cancer of the head of the pancreas.
… high dose intravenous vitamin C may help improve the quality of life of those who develop cancer.
Although not a large grant, it’s significant because it represents a breakthrough for us in receiving foundation support from outside our geographic area. The support has come in recognition of our pioneering efforts to demonstrate that nutritional medicine may offer significant help to those who have developed cancer and to those who want to have a better chance of not getting it in the first place.
Since 1980, The Center has shown in several patients that high dose intravenous vitamin C may help prolong life and improve the quality of life of those who develop cancer.
RECNAC project, The Center’s cancer research arm, exists for much the same reason that The Center itself exists: to fill a void in standard medicine and standard research. The Center is looking where no one else has looked. It’s not easy, but we have discovered where to look in less convenient places, perhaps because, as Doctor Harold Rusch once said, “we let our minds wander more.”
The grant from the Wallace Genetic Foundation will be used for the nutritional evaluation and treatment of two people diagnosed with this deadly form of cancer. The patients must have been diagnosed through tissue biopsy and may have had surgery but may not have undergone chemotherapy or radiation treatment. The participants must also be free of liver metastases.
“I’ve written to physicians in the Wichita area advising them of the availability of this research and treatment project, asking that if they encounter patients who might be interested in this approach, to let them know. There would be no charge for any of the extensive biochemical evaluations performed or therapy administered as part of the research protocol,” Dr. Riordan said.
Generally, the survival time for people diagnosed with cancer of the head of the pancreas is extremely short. Our research study will be based on our cell culture research which resulted in a scientific paper being written titled: “Intravenous Ascorbate as a Tumor Cytotoxic Chemotherapeutic Agent.”